Medical Patent News

RSS

USPTO reconfirms Hovione's patent claims to flumethasone, reverses rejection

Hovione and Dickstein Shapiro LLP are pleased to announce that the U.S. Patent and Trademark's Board of Patent Appeals and Interferences has reconfirmed Hovione's patent claims to a method of making flumethasone and its 17-carboxyl androsten analogue, two key intermediates on the synthesis of fluticasone, an important corticosteroid used in asthma medications, reversing a rejection by the reexamination examiner.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.

3 Nov 2010

Zynx Health's clinical support solution receives US patent

Zynx Health, the market leader in providing evidence-based and experience-based clinical decision support solutions, today announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent 7,822,626 covering their extensive suite of tools that facilitate and enhance the capability within a healthcare institution to establish and maintain an evidence-based best practice approach to providing patient care.

2 Nov 2010

National Jewish Health's chronic urticaria diagnostic assay receives US patent

National Jewish Health has received a US patent for a method of detecting autoimmune chronic urticaria, which will help assure many patients that dramatic changes in lifestyle are not needed to treat the condition.

2 Nov 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Metagenics, Inc. has been awarded two new patents for discoveries relating to its research on the anti-inflammatory properties of reduced iso-alpha acids (RIAA) derived from hops. Metagenics is a life sciences company focused on reversing chronic illness and improving health through therapeutic nutrition and lifestyle changes. The discoveries were made by researchers at Metagenics’ wholly-owned biotechnology subsidiary, MetaProteomics® LLC.

28 Oct 2010

USPTO rejects patent claims asserted against Precision BioSciences

Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued Final Decisions and Right of Appeal Notices in the reexamination proceedings for U.S. Pat. Nos. 6,833252, 7,214,536, 6,610,545 and 7,309,605 that are owned by the Institut Pasteur and the Universite Pierre et Marie Curie, and licensed to Cellectis, SA (ALCLS).

28 Oct 2010

AnaptysBio announces issuance of two new patents for SHM-XEL platform

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced the issuance of patents in the US and Europe that provide additional coverage for its SHM-XEL platform. These patents extend AnaptysBio's leadership in the use of somatic hypermutation (SHM) for the discovery and optimization of antibodies and other proteins.

28 Oct 2010

CutisPharma receives U.S patent for suppository compounding

CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,815,929) regarding a method for the preparation, storage and dispensing of compounded suppositories.

28 Oct 2010

IBI receives U.S. patent for novel blood protein biomarkers

Intrinsic Bioprobes today announced that the United States Patents and Trademark Office has issued US Patent 7,816,095 covering novel blood protein biomarkers related to cardiovascular disease. This patent is first of a series of patent applications that cover specific human protein variants as biomarkers with clinical utility.

28 Oct 2010

Rockwell receives SFP patent for GMP formulation

Rockwell Medical a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Office for patent issuance on its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead-drug candidate for treating iron deficiency anemia in ESRD patients.

27 Oct 2010

Sirius receives U.S. patent for using SNP in Protein C gene

Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.

27 Oct 2010

Momenta receives patent for methods to evaluate enoxaparin

Momenta Pharmaceuticals, Inc. a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,816,144, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin by analyzing chain sequence information.

26 Oct 2010

Trius receives patent protection for torezolid phosphate in the U.S.

Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).

26 Oct 2010

PhRMA representatives meet with officials in India to discuss compulsory licensing

During a visit with government officials, industry leaders and NGOs in India last week, representatives from Pharmaceutical Research and Manufacturers of America (PhRMA), a U.S. lobbying group that represents the country's pharmaceutical industry and biotechnology companies, addressed "the Indian government's proposal to allow local drugmakers to make low-cost version of patented drugs so that they can be made available to patients," the Economic Times reports.

26 Oct 2010

Helicos names Illumina and Life Technologies as additional defendants in lawsuit against Pacific Biosciences

Helicos BioSciences Corporation announced today that it has amended its lawsuit against Pacific Biosciences of California, Inc. for patent infringement by naming Illumina, Inc. and Life Technologies Corporation as additional defendants.

From Illumina, Inc. 25 Oct 2010

Occlutech receives favorable appeal court ruling against patent litigation with AGA Medical

Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable appeal court ruling from The Hague, The Netherlands in the on-going patent litigation with AGA Medical. A favourable first instance court ruling obtained by Occlutech had been appealed by AGA in 2008.

22 Oct 2010

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Celtic Pharmaceutical Holdings L.P. today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept with Avastin.

22 Oct 2010

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010